Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer.
chemoresistance
endometrial cancer
immune checkpoint
overall survival
programmed death ligand 2
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
02
2020
accepted:
18
09
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
epublish
Résumé
In cancer, upregulation of coinhibitory B7 ligands has been associated with immune evasion. So far, anti-programmed death-1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies have been used in immuno-oncology, with promising outcomes; however, it is still needed to identify other markers, especially for endometrial cancer (EC). EC is a gynecological malignancy historically classified into two types: type I, with mostly estrogen-dependent endometrioid diseases, and the most aggressive type II, including mainly estrogen-independent and non-endometrioid tumors. PD ligand-2 (PD-L2) is known as the second ligand of the PD-1 receptor and, upon its binding, contributes to T-cell exhaustion. Up to now, very few information are available about PD-L2 in cancers, and no data have been reported for EC. The aim of this work was to characterize the PD-L1 and PD-L2 ligand expression profile in EC cell lines, focusing the attention on the biological role of PD-L2 and its prognostic impact in human type II EC biopsies. Using
Identifiants
pubmed: 33194598
doi: 10.3389/fonc.2020.538064
pmc: PMC7656062
doi:
Types de publication
Journal Article
Langues
eng
Pagination
538064Informations de copyright
Copyright © 2020 Marinelli, Annibali, Morelli, Zeppa, Tuyaerts, Aguzzi, Amantini, Maggi, Ferretti, Santoni, Amant and Nabissi.
Références
Oncotarget. 2017 Dec 25;9(4):5274-5286
pubmed: 29435178
Oncotarget. 2016 May 31;7(22):32113-28
pubmed: 27050074
Hum Pathol. 2018 Jan;71:91-99
pubmed: 29122656
Mol Med Rep. 2019 Jun;19(6):4529-4535
pubmed: 30942405
Br J Cancer. 2018 Jul;119(1):80-88
pubmed: 29921949
Appl Immunohistochem Mol Morphol. 2018 Aug;26(7):e79-e85
pubmed: 29271789
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Int J Mol Sci. 2018 Aug 13;19(8):
pubmed: 30104481
Cancer Treat Rev. 2017 Sep;59:109-116
pubmed: 28800469
Oncoimmunology. 2018 Nov 20;8(2):e1541535
pubmed: 30713802
Exp Ther Med. 2015 Nov;10(5):1947-1952
pubmed: 26640578
Cell Death Dis. 2019 Mar 18;10(4):261
pubmed: 30886151
Front Oncol. 2019 Oct 15;9:1073
pubmed: 31681606
Trends Biochem Sci. 2011 Jun;36(6):320-8
pubmed: 21531565
J Thorac Oncol. 2015 Dec;10(12):1726-35
pubmed: 26473645
Br J Cancer. 2006 Mar 13;94(5):642-6
pubmed: 16495918
Clin Dev Immunol. 2012;2012:656340
pubmed: 22611421
Cancer Sci. 2016 Jun;107(6):726-33
pubmed: 27015293
Front Oncol. 2019 Feb 13;9:47
pubmed: 30891423
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Cancer Res. 2016 Dec 1;76(23):6964-6974
pubmed: 27671674
Signal Transduct Target Ther. 2018 Sep 28;3:26
pubmed: 30275987
Int J Gynecol Pathol. 2019 Sep;38(5):404-413
pubmed: 30134343
Oncol Lett. 2016 Jan;11(1):16-22
pubmed: 26834851
Endocr Relat Cancer. 2016 Feb;23(2):R85-R111
pubmed: 26538531
J Gynecol Oncol. 2019 May;30(3):e46
pubmed: 30887763
Front Immunol. 2016 Dec 12;7:550
pubmed: 28018338
Cell Physiol Biochem. 2017;43(5):1893-1906
pubmed: 29055949
Blood. 2008 Apr 1;111(7):3635-43
pubmed: 18223165
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
Oncol Lett. 2016 Aug;12(2):944-950
pubmed: 27446374
Cancer Immunol Immunother. 2014 Jun;63(6):545-57
pubmed: 24658839
Am J Clin Exp Urol. 2016 Jan 28;4(1):1-8
pubmed: 27069956
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50
pubmed: 30306580
Oncotarget. 2016 Oct 11;7(41):66558-66568
pubmed: 27589685
Arch Pathol Lab Med. 2014 May;138(5):595-601
pubmed: 24236805
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Mol Hum Reprod. 2007 May;13(5):317-22
pubmed: 17350964